Literature DB >> 18053636

Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi.

Pierre I Karakiewicz1, Nazareno Suardi, Claudio Jeldres, Pascale Audet, Pierre Ghosn, Jean-Jacques Patard, Paul Perrotte.   

Abstract

A 75-yr-old previously healthy woman presented with gross hematuria, European Cooperative Oncology Group 0, and an 11-cm renal mass with right atrial thrombus. The patient refused the sternotomy. She was offered two cycles of sunitinib maleate (Sutent) induction therapy to down-stage the thrombus and to reduce the extent of the surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18053636     DOI: 10.1016/j.eururo.2007.11.006

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  32 in total

Review 1.  Treatment of metastatic renal cell carcinoma.

Authors:  Maxine Sun; Giovanni Lughezzani; Paul Perrotte; Pierre I Karakiewicz
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

Review 2.  [Systemic and surgical management of metastatic renal cell carcinoma].

Authors:  M W Kramer; A S Merseburger; I Peters; S Waalkes; M A Kuczyk
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

3.  Early ultrasonographic evaluation of tumor thrombus level during sunitinib therapy for renal cell carcinoma.

Authors:  Futoshi Sano; Syusei Fusayasu; Shinji Otake; Hiroyuki Yamanaka; Tomoyuki Tatenuma; Ryoko Sakata; Kazuhide Makiyama; Noboru Nakaigawa; Masahiro Yao; Yoshinobu Kubota
Journal:  J Med Ultrason (2001)       Date:  2013-05-01       Impact factor: 1.314

4.  Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma.

Authors:  Vincenzo Ficarra; Giacomo Novara
Journal:  Nat Rev Urol       Date:  2010-02       Impact factor: 14.432

Review 5.  Clinical management of renal cell carcinoma with venous tumor thrombus.

Authors:  Nnenaya Agochukwu; Brian Shuch
Journal:  World J Urol       Date:  2014-04-22       Impact factor: 4.226

Review 6.  Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Authors:  Adrian Husillos Alonso; Manuel Carbonero García; Carmen González Enguita
Journal:  World J Nephrol       Date:  2015-05-06

Review 7.  The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.

Authors:  Pierre Bigot; Souhil Lebdai; Alain Ravaud; Abdel Rahmène Azzouzi; Jean-Marie Ferrière; Jean-Jacques Patard; Jean-Christophe Bernhard
Journal:  World J Urol       Date:  2013-03-30       Impact factor: 4.226

8.  Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Authors:  Axel Bex; Astrid A M van der Veldt; Christian Blank; Alfons J M van den Eertwegh; Epie Boven; Simon Horenblas; John Haanen
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

9.  Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.

Authors:  Jing Wang; Shuzhi Wu; Tianren Huang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

Review 10.  Molecular diagnosis and therapy of kidney cancer.

Authors:  W Marston Linehan; Gennady Bratslavsky; Peter A Pinto; Laura S Schmidt; Len Neckers; Donald P Bottaro; Ramaprasad Srinivasan
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.